GuidelineClinical infectious diseases : an official publication of the Infectious Diseases Society of America2000
Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group.
Guideline in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00046267. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study of the Safety, Efficacy, and Tolerability of Extended-Release Niacin (Niaspan) for the Treatment of Elevated Non-HDL Cholesterol and Elevated Triglycerides in HIV-Infected Subjects
Open the trial in the graphA Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 199 citations in OpenAlex.
- Evaluation and management of dyslipidemia in patients with HIV infection.Journal of general internal medicine · 2002Pooled it
- Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.AIDS (London, England) · 2009Trial
- Metabolic Profile of People Living with HIV in a Treatment Hub in Manila, Philippines: A Pre- and Post-Antiretroviral Analysis.Journal of the ASEAN Federation of Endocrine Societies · 2022Review
- Manifestations and Related Risk Factors of Thrombocyte Abnormalities in HIV-Positive Patients Before and After the Initiation of ART.Infection and drug resistance · 2021Article
- Aortic stiffness and central hemodynamics in treatment-naïve HIV infection: a cross-sectional study.BMC cardiovascular disorders · 2020Article
- Cardiovascular risk factors among Ghanaian patients with HIV: A cross-sectional study.Clinical cardiology · 2019Article
- Diabetes and HIV: current understanding and future perspectives.Current diabetes reports · 2013Review
- Cardiovascular disease risk factors among HIV-infected Nigerians receiving highly active antiretroviral therapy.Nigerian medical journal : journal of the Nigeria Medical Association · 2013Article
- Self-reported body changes and associated factors in persons living with HIV.Journal of health, population, and nutrition · 2010Article
- Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study.International journal of clinical practice · 2010Article
- Rhabdomyolysis: a case study exploring the possible side effect of lipid lowering medication by a HIV positive patient taking a protease inhibitor.The Journal of the Canadian Chiropractic Association · 2008Article
- Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2008Article
- Lipid lowering effects of Momordica charantia (Bitter Melon) in HIV-1-protease inhibitor-treated human hepatoma cells, HepG2.British journal of pharmacology · 2006Article
- Adverse effects of antiretroviral therapy for HIV infection.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2004Review
- Cardiovascular Complications in Patients with HIV Infection.Current infectious disease reports · 2003Article
- HIV and cardiovascular medicine.Heart (British Cardiac Society) · 2003Review
- Coronary artery disease in HIV infected patients.Intensive care medicine · 2003Article
- HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages.The Journal of clinical investigation · 2003Article
- HIV disease and advanced age: an increasing therapeutic challenge.Drugs & aging · 2002Review
- Cardiovascular manifestations of HIV infection.Journal of the Royal Society of Medicine · 2001Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dyslipidemia is a prevalent condition that affects patients infected with human immunodeficiency virus (HIV) who are receiving antiretroviral therapy. These preliminary recommendations summarize the current understanding in this area and propose guidelines for management. Existing guidelines for the management of dyslipidemia in the general population formed the general basis for our recommendations. Data on the prevalence and treatment of dyslipidemia of HIV-infected patients, implications of treatment-related dyslipidemia in other chronically ill populations, and pharmacokinetic profiles for the available hypolipidemic agents in non-HIV populations were considered. Although the implications of dyslipidemia in this population are not fully known, the frequency, type, and magnitude of lipid alterations in HIV-infected people are expected to result in increased cardiovascular morbidity. We propose that these patients undergo evaluation and treatment on the basis of existing guidelines for dyslipidemia, with the caveat that avoidance of interactions with antiretroviral agents is paramount.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.